The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Al Benson III elected president of National Patient Advocate Foundation executive board

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

AL BENSON III was elected president of the National Patient Advocate Foundation’s executive board.

Benson is associate director for cooperative groups at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. He has served on the foundation’s board for three years and also served on the scientific advisory committee since 2009.

“I am honored to serve as the National Patient Advocate Foundation’s Board President. NPAF is a leader in fighting for improvements in the healthcare system at the state and federal level,” Benson said. “We will continue our 20 year history of helping those living with serious illness by promoting bills like the Medical Debt Relief Act, 21st Century Cures, Innovation for Healthier Americans and other initiatives designed to address access and affordability issues for patients.”

Table of Contents

YOU MAY BE INTERESTED IN

Perspective

ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations

 For nearly 30 years, the American Cancer Society’s prostate cancer screening guidelines have advised men to discuss prostate-specific antigen, or PSA, testing with a clinician and weigh potential benefits and harms, rather than treat screening as an unquestioned routine. This “informed decision-making” recommendation was consistent with guidelines from all major professional organizations in the United States, Canada, and Europe. 
By Otis W. Brawley and Ian Schonman
Sponsored

Clinical trial aims to personalize treatment for patients with HPV-related throat cancer
Blood-based protocol could reduce treatment burden while preserving quality of life after surgery

For patients with an HPV-related form of throat cancer, treatment is often highly effective, with cure rates as high as 90%, depending on the disease stage. Now, researchers are investigating whether some patients can safely avoid additional treatment while maintaining excellent cancer outcomes.
By Hayley Kamin
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account